US EditionPublished • loading... • Updated
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Summary by themarketsdaily.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple trials underway. Strategy: From platform to clinical-stage focus CEO Carmine Stengone described Contineum as a small-molecule […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
